Delving into the Latest Updates on Semaglutide(Sinopep-Allsino) with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms-

Target

GLP-1R

Mechanism

GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 2Obesity

Inactive Indication-

Originator Organization

Sinopep-Allsino Bio Pharmaceutical Co., Ltd.

Active Organization

Sinopep-Allsino Bio Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价在健康成年受试者中单次给药受试制剂司美格鲁肽注射液与参比制剂司美格鲁肽注射液（诺和泰®）药代动力学（PK）特征的相似性。次要目的：评价受试制剂司美格鲁肽注射液与参比制剂司美格鲁肽注射液（诺和泰®）在健康受试者中的安全性。

[Translation]

Primary objective: To evaluate the similarity of the pharmacokinetic (PK) characteristics of the test preparation semaglutide injection and the reference preparation semaglutide injection (Novota®) after a single dose in healthy adult subjects. Secondary objective: To evaluate the safety of the test preparation semaglutide injection and the reference preparation semaglutide injection (Novota®) in healthy subjects.

Start Date-

Sponsor / Collaborator

Sinopep-Allsino Bio Pharmaceutical Co., Ltd.

100 Clinical Results associated with Semaglutide(Sinopep-Allsino)

Login to view more data

100 Translational Medicine associated with Semaglutide(Sinopep-Allsino)

Login to view more data

100 Patents (Medical) associated with Semaglutide(Sinopep-Allsino)

Login to view more data

100 Deals associated with Semaglutide(Sinopep-Allsino)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 1	CN	Sinopep-Allsino Bio Pharmaceutical Co., Ltd.	11 Oct 2024
Obesity	IND Approval	CN	Sinopep-Allsino Bio Pharmaceutical Co., Ltd.	11 Sep 2024